Immunologic outcomes. (A) Immunologic impact of 12 weeks of low-dose IL-2: median Treg, Tcon count, and Treg:Tcon ratio in the study cohort during 12-week IL-2 and 4 weeks off IL-2. Line with arrows indicates IL-2 therapy. Box-and-whisker plots indicate median and IQR for healthy donors. Number of patients evaluated at each time point is indicated at the bottom. (B) Treg:Tcon ratios and IL-2 clinical response: week 0 and week 1 Treg:Tcon ratios in clinical responders (R: PR) and nonresponders (NR: PD/SD/MR) are displayed separately. Each line indicates an individual patient’s data at baseline and week 1. Threshold ratios of 0.07 (baseline) and 0.20 (week 1) are indicated by the dashed lines. (C) Naive and EM Treg percentage by IL-2 clinical response: week 0 and week 1, 2, and 4 naive and EM Treg percentage for clinical responders (R: PR) and nonresponders (NR: PD/SD/MR) are displayed separately. P values at relevant time points are indicated. Number of patients evaluated at each time point is indicated at the bottom. (D) Plasma IL-2, sIL-2R, and Treg cell counts during IL-2 therapy. Median plasma IL-2, plasma sIL-2R, and Treg cell counts during 12-week IL-2 and 4 weeks off IL-2. Box-and-whisker plots indicate median and IQR for healthy donors. Number of patients evaluated at each time point is indicated at the bottom of the image.